Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23216136 | 0.81 | KDM1A (0.36) | HTR2CDRD2DRD1TSHRHSD17B10 | |
| SCHEMBL16736586 | 0.81 | CYP3A4 (0.37) | HTR2CDRD2DRD1HPGDHSD17B10 | |
| SCHEMBL18587275 | 0.81 | LMNA (0.46) | HTR2CCHRNB2CHRNA4DRD2DRD1 | |
| SCHEMBL18587165 | 0.81 | CHRNB2 (0.31) | CHRNB2CHRNA4HPGDTSHRHSD17B10 | |
| SCHEMBL18587191 | 0.81 | GAA (0.42) | CHRNB2CHRNA4DRD2DRD1HPGD | |
| SCHEMBL29588427 | 0.81 | LMNA (0.46) | HTR2CCHRNB2CHRNA4DRD2DRD1 | |
| SCHEMBL68378 | 0.77 | HSP90AA1 (0.44) | HTR2CHPGDTSHRHSD17B10NUDT1 | |
| SCHEMBL16117971 | 0.77 | HSD17B10 (0.42) | HPGDTSHRHSD17B10HSP90AA1THRB | |
| SCHEMBL22560913 | 0.77 | TSHR (0.34) | HPGDTSHRHSD17B10HSP90AA1 | |
| SCHEMBL18587676 | 0.77 | AR (0.37) | DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | HTR2C 193/4885CHRNB2 188/4885CHRNA4 105/4885 |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | HTR2C 193/4885CHRNB2 188/4885CHRNA4 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.